Could chemo after surgery keep esophageal cancer at bay?
NCT ID NCT04174079
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This trial investigates whether giving chemotherapy (docetaxel and nedaplatin) after surgery can prevent esophageal cancer from returning. Patients with a certain stage of thoracic esophageal squamous cell carcinoma who had their tumor fully removed are randomly assigned to receive chemotherapy or just be observed. The main goal is to see if the chemo group has a longer period without cancer recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy with docetaxel and nedaplatin
- What this could lead to
- If successful, this could establish a standard adjuvant chemotherapy regimen to reduce cancer recurrence after surgery for esophageal cancer.
- What could go wrong
- This is a single-center trial with 232 participants, and the chemotherapy may cause side effects like low blood counts and nerve damage. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Uniersity Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.